AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03743233 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hand file
Description: A crown-down technique will be performed until reaching the provisory WL. The root canals will be initially deobstructed with size #3 and #2 Gates-Glidden burs (Dentsply-Maillefer) at the coronal and middle root thirds. Then, hand stainless steel K-files (Dentsply-Maillefer) with decreasing sizes will be used (#40, #35, #30, #25). The WL will be determined by an electronic apex locator (Novapex; Forum Technologies, Rishon Le-Zion, Israel). A radiograph will be taken to confirm the WL, which should be 1 mm short of the root apex. Apical patency will be reached and maintained with a size #15 K-file (Dentsply-Maillefer). The root canals will be reinstrumented and a size #50 K-file will be standardized as the master apical instrument. A step-back procedure in 1-mm increments followed until merging with the crown-down rotary enlargement (size #70) will be achieved.
Study NCT03743233 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reciprocating
Description: Reciproc R25 file will be used for gutta-percha removal, until reaching the WL. The instrument will be introduced into the canal applying slight movements of 3-mm amplitude. Apical patency will be maintained with a size #15 K-file. The root canals will be reinstrumented using the Reciproc R50 file. For both groups, after the root canal filling removal and reinstrumentation protocol, a new radiograph will be taken, without any intracanal instrument, for posterior analysis of the percentage of remaining filling material in the root canal. If the radiograph demonstrates the persistence of filling material, the technique will be repeated with the last instrument used in the chemomechanical preparation (hand or reciprocating file), also using H-files with circumferential movements against the dentinal walls in order to remove these residual material, followed by abundant irrigation with NaOCl.
Study NCT00646126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadoxine / Pyrimethamine (SP) plus artesunate (AS)
Description: Standard three day regimen
Study NCT00646126 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablet similar to active drug in shape and size
Description: Dosage similar to active drug(standard three days regimen)
Study NCT04255771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Standard GC (gemcitabine and cisplatin) regimen: gemcitabine 1000-1200mg/m2 intravenous infusion on days 1 and 8, cisplatin 70mg/m2 on the second day of intravenous infusion, every 3 weeks (21-day regimen) is a cycle, A total of 3 cycles.
Study NCT04255771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Use a placebo as a comparison
Study NCT03200470 — intervention group
Intervention type: OTHER
Intervention: No intervention: sample collection study
Description: Sample collection and collection of laboratory values
Study NCT04032158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avonex®
Description: Participants received avonex® IM injection once a week.
Study NCT04032158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avonex® matched Placebo
Description: Participants received IM injection of placebo matched to Avonex® once a week.
Study NCT03997864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prazosin
Description: Starting dose: 2mg at HS. Maximum dose: 15 mg at HS. Dosage will be increased 1 mg every 3 days until sleep is improved, max dose is reached, or side effects are problematic.~Tapering Decrease prazosin 1 mg every 3 days or 3 mgs per week until off completely. Tapering will take approximately 2-3 weeks.
Study NCT03997864 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Starting dose: 2mg at HS. Maximum dose: 15 mg at HS. Dosage will be increased 1 mg every 3 days until sleep is improved max dose is reached, or side effects are problematic.
Study NCT01302184 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat®
Description: Patients of the experimental group were trained at 50% of BWS for 15 minutes and 30% of BWS for 15 minutes on the Lokomat®. Treadmill speed was initiated at 1.5km/h and increased to 3.0km/h by increments of 0.5km/h as tolerated.~A physical therapist supervised the treatment, adjusting treadmill speed and BWS.~Treatment was performed for 3 days/week, for 4 weeks
Study NCT01302184 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill
Description: Patients of the control group had 30 minutes of treadmill gait training. After having calculated the speed during 6MWT, the patient was trained on a treadmill (RHC770CE - RAM Medical srl). They were trained using 80% of the maximum speed that the patient reached during the test for the first week, 90% for the second week, 100% for the third and fourth week.~A Physical Therapist provided auditory cueing and direct, continuous feed-back to the patient.~Treatment was performed for 3 days/week, for 4 weeks.
Study NCT04456907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: Autologous platelet-rich plasma (PRP) was prepared using the RegenKit THT system (RegenLab SA, Le Mont-sur-Lausanne, Switzerland) following the manufacturer's instructions. Medical technicians, who had been well-trained by the manufacturer, were responsible for the process of PRP preparation. For each patient, 8-10 mL of venous blood was drawn and collected to the commercial RegnLab THT tube, which contained 1 mL sodium citrate. After single centrifugation at 3400 revolutions per minute (rpm) for 8 minutes, 4-5 mL of PRP was yielded with leukocytes maintained at physiological levels and red blood cells depleted. Then, the blood components were separated, with the platelet pellet resting on the separating gel. PRP for later application was obtained by re-suspending the platelet pellet in the plasma supernatant by gently inverting the unopened RegenKit THT tube 5 to 10 times.
Study NCT04456907 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: saline injection
Description: saline injection
Study NCT03089814 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ischemic conditioning
Description: Four cycles of 5-min inflation of pneumatic cuff on upper extremity up to 200 mmHg, followed by 5-min deflation with no pressure.
Study NCT04373421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate 0.12 % Mouthwash + benzydamine hydrochloride
Description: After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
Study NCT04373421 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: St. John's wort oil
Description: After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
Study NCT04373421 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Virgin olive oil
Description: After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
Study NCT01877174 — intervention group
Intervention type: DEVICE
Intervention: MICHI(TM) NPS+f
Description: Transcarotid delivery system for carotid stents with flow reversal
Study NCT01877174 — intervention group
Intervention type: PROCEDURE
Intervention: transcarotid stenting
Study NCT02006264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF Intravaginal Ring
Description: The TDF IVR intravaginal ring is formulated using flexible outer tubing, comprised of hydrophilic, aliphatic polyether urethane, and an inner core compartment comprised of 86% w/w TDF and 14% w/w sodium chloride (NaCl). The TDF intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
Study NCT02006264 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Intravaginal Ring
Description: The placebo ring is formulated using flexible outer tubing, comprised of hydrophilic, aliphatic polyether urethane, and an inner core comprised of sodium chloride (NaCl). The Placebo intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
Study NCT00773565 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Optifast
Description: Formula diet for twelve weeks combined with physical activity and behavioral therapy
Study NCT00613418 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: IDev SUPERA® Interwoven Self Expanding Nitinol Stent Peripheral Vascular System
Description: Interwoven, self-expanding nitinol stent system, including delivery system and stent
Study NCT00980343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vismodegib
Description: Given orally
Study NCT00980343 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: undergo surgery
Study NCT00980343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: correlative studies
Study NCT00980343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: correlative studies
Study NCT02215408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CVRS Intervention
Description: A clinical pharmacist working in the University of Iowa CVRS followed each patient for 12 months, working on lifestyle modification and recommending medication changes to the patient's clinical pharmacist in the local clinic.
Study NCT03956225 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Systane iLux® Dry Eye System
Description: Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
Study NCT03956225 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LipiFlow® Thermal Pulsation System
Description: Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
Study NCT03659370 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fumigation
Description: use Fumigation to increase the improvement of osteoarthritis of knee
Study NCT03659370 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture
Study NCT00421603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adderall-XR and Topiramate
Description: Adderall-XR 60mg/day and Topiramate 300mg/day
Study NCT00421603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01234363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastography, and Supersonic Shear Imaging
Description: Magnetic Resonance Elastography, and Supersonic Shear Imaging
Study NCT02423291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Brentuximab vedotin, 1.8 mg/kg, administered via outpatient IV infusion on Day 1 of each 21-day cycle.
Study NCT03306485 — intervention group
Intervention type: OTHER
Intervention: Correlating the number of reflux episodes detected on 1-h post prandial esophageal high resolution manometry combined and those detected on ambulatory 24-h pH-impedance monitoring performed on PPI
Description: Esophageal high resolution impedance manometry (HRIM) consists of introducing a transnasal probe to record esophageal contractility (manometry), bolus transit (impedance) but also the occurrence of reflux episodes. Ambulatory 24-h pH-impedance monitoring consists of recording the occurrence of reflux episodes by introducing a transnasal catheter into the esophagus. After inserting the transnasal HRIM probe and the pH-impedance catheter, both HRIM and 24-h pH-impedance recordings are started. The patient is instructed to eat a meal that induces reflux symptoms (the patient brings his own meal). One hour the end of the meal, the HRIM probe is removed. The patient is discharged at home and the 24-h pH-impedance monitoring is continued. The patient is coming back 24-h after catheter insertion to stop the pH-impedance recording and remove the catheter.
Study NCT02763293 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Non-manipulative treatment osteopathic techniques combined direct and indirect soft appropriate in patients with Crohn's disease
Study NCT03172858 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracervical balloon catheter
Description: cervical ripening balloon
Study NCT03172858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: medication used to induce contractions
Study NCT03172858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: medication used to induce contractions
Study NCT00418964 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single bundle hamstring
Description: Single bundle hamstring
Study NCT00418964 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double bundle hamstring
Description: Double bundle hamstring
Study NCT00418964 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone patellar tendon bone
Description: Bone patellar tendon bone
Study NCT01062568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenocorticotropin
Description: Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.
Study NCT01062568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, 0.25 mg adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.
Study NCT01909167 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Cognitive Behavioral Therapy (CBT)
Description: CBT treatment: Patients randomized to the online treatment will have, in total, 10 real time individual sessions of 40min each, starting at the 20-23rd gestational week and lasting until 6 weeks postpartum. The therapy will be delivered every two weeks, with a break from the 36th gestational week until the 4th week postpartum.
Study NCT01909167 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Patients randomized to the treatment as usual arm will be advised by their GP,perinatal psychiatric team or mental health midwife concerning treatment.
Study NCT03957798 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RecoveryWarrior 2.0
Description: RecoveryWarrior 2.0 was developed for use with Microsoft Kinect running on a Windows personal computer. All games made use of whole-body motion detection and the same voice-recognition feature. Body motions included a variety of arm, leg, and whole-body movements to physically enact the motions of destroying or evading images of drugs and drug paraphernalia. Voice features consisted of recognition of the refusal phrase I'm Clean Players could say or shout I'm Clean in order to gain additional strength for their game play avatar. All game art was created in a hyperrealistic, idealized, heroic style.
Study NCT04665440 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Voice alone
Description: mother's voice without tactile stimuli
Study NCT04665440 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Voice + tactile stimuli
Description: mother's voice with tactile stimuli
Study NCT01414738 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Hippocampal-Avoiding Whole Brain Irradiation with Simultaneous Integrated Boost
Study NCT04204993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumee Oxygen Platform
Description: Two sensors will be inserted (one in the skin fo the upper arm and one on the side of the chest). A wireless patch reader is placed on top of the skin over the area where the sensor has been placed to measure local oxygen content.
Study NCT01831700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril and Hydrochlorothiazide Tablets (20+25) mg
Description: Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day
Study NCT01831700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril and Hydrochlorothiazide Tablets (20+25) mg
Description: Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day
Study NCT01831700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets
Description: Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day
Study NCT04032158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evobrutinib matched Placebo
Description: Participants received placebo matched to evobrutinib twice a day.
Study NCT01831700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets
Description: Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day
Study NCT02214160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UX007
Description: Administered orally (PO) with food or by gastrostomy tube, at the target dose range of 25-35% of total calories.
Study NCT00331071 — intervention group
Intervention type: DRUG
Intervention: Monophasic or triphasic Oral contraceptive tablet
Description: fourth week is patch free
Study NCT00331071 — intervention group
Intervention type: DRUG
Intervention: Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE
Description: worn for 1 week and replaced for 3 consecutive weeks
Study NCT01300052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2728 ointment, 2%
Description: AN2728 ointment, 2%, applied twice daily for 12 weeks
Study NCT01300052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ointment Vehicle
Description: Ointment Vehicle, applied twice daily for 12 weeks
Study NCT03145402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of stem cell
Description: Autologous bone marrow-derived mononuclear cells are obtained from 100-150ml of bone marrow aspirated under local anaesthesia from the iliac crest. Intracoronary infusion of the cells is performed in patients with Heart failure via conventional percutaneous intracoronary intervention techniques.
Study NCT03145402 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of Placebo in patients with Heart failure via coronary arteries
Study NCT03433755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evolocumab
Description: Evolocumab will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive evolocumab (AMG 145) every 2 weeks or monthly subcutaneously.
Study NCT03433755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be administered per pre-filled auto-injector pen (AI/Pen). Participants will receive placebo every 2 weeks or monthly subcutaneously.